Shapiro A G, Thomas L
South Med J. 1984 Jun;77(6):719-21. doi: 10.1097/00007611-198406000-00014.
Fifty postpartum patients were randomly given either bromocriptine (2.5 mg by mouth b.i.d. X 30 doses) or breast binders for inhibiting lactation. The breast binder group had a high incidence of symptoms (breast pain, engorgement, secretion) for the first week postpartum; these symptoms rapidly decreased by the second week. Bromocriptine successfully suppressed the breast problems in virtually all of the patients who took the drug correctly. Because of the high rate of side effects and a significant incidence of "rebound," the dosage of bromocriptine should probably be changed, and we recommend a revised dosage.
五十名产后患者被随机给予溴隐亭(口服2.5毫克,每日两次,共30剂)或乳房束缚带以抑制泌乳。乳房束缚带组在产后第一周出现症状(乳房疼痛、胀痛、分泌)的发生率较高;这些症状在第二周迅速减轻。溴隐亭几乎在所有正确服用该药的患者中成功抑制了乳房问题。由于副作用发生率高且“反跳”发生率显著,溴隐亭的剂量可能需要改变,我们建议修订剂量。